Russell Investments Group
VERV

Russell Investments Group’s Verve Therapeutics VERV Stock Holding History

Russell Investments Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-166
Closed -$1.86K – 4231
2025
Q2 		$1.86K Sell
166
-35,531
-100% -$203K ﹤0.01% 3598
2025
Q1 		$163K Sell
35,697
-40,341
-53% -$270K ﹤0.01% 2646
2024
Q4 		$429K Sell
76,038
-29,355
-28% -$166K ﹤0.01% 2322
2024
Q3 		$510K Buy
105,393
+22,159
+27% +$129K ﹤0.01% 2271
2024
Q2 		$406K Buy
83,234
+82,820
+20,005% +$521K ﹤0.01% 2272
2024
Q1 		$5.5K Buy
414
+391
+1,700% +$5.18K ﹤0.01% 2930
2023
Q4 		$321 Buy
+23
New +$285 ﹤0.01% 3152
2023
Q3 		– Sell
-23
Closed -$431 – 3631
2023
Q2 		$431 Hold
23
– – ﹤0.01% 3371
2023
Q1 		$332 Buy
+23
New +$450 ﹤0.01% 3215

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Russell Investments Group's VERV Position: Q3 2025 in Review

Russell Investments Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 166 shares — an estimated $1.86K sold.

Russell Investments Group first reported a position in VERV in Q1 2023 and held it in 9 quarters. The position peaked at $510K in Q3 2024. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Russell Investments Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Russell Investments Group sold 166 Verve Therapeutics shares in Q3 2025, an estimated $1.86K.
  • Russell Investments Group first reported a position in Verve Therapeutics in Q1 2023 and held it in 9 quarters.
  • Russell Investments Group's Verve Therapeutics position peaked at $510K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Russell Investments Group's 13F filing for Q3 2025, filed 13 Nov 2025.